Article

CAT quits plans for scar-tissue treatment

Cambridge, England—Cambridge AntibodyTechnology's (CAT) potential treatment for improving trabeculectomy outcomes has failed to meet the primary endpoint in its second pivotal clinical trial and will be discontinued.

Cambridge, England-Cambridge AntibodyTechnology's (CAT) potential treatment for improving trabeculectomy outcomes has failed to meet the primary endpoint in its second pivotal clinical trial and will be discontinued. The treatment, called Trabio, referred to a human monoclonal antibody designed to neutralize transforming growth factor beta-2, a protein produced in response to eye injury and believed to be responsible for the growth of excessive scar tissue after glaucoma surgery.

Results from earlier clinical trials showed lower IOP and reduced postoperative intervention following Trabio treatment. However, the international phase III trial results are consistent with the first pivotal clinical trial, and the company is terminating further development.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.